Personalized Treatment for Blood Cancer
- Conditions
- Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive
- Registration Number
- CTRI/2019/10/021533
- Lead Sponsor
- R Saravanabhavan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients who are already under the treatment for Chronic Myeloid Leukaemia
Patients of both male and female sexes are included
Age range of the patients should be 18 to 85 should have completed 18 years before taking part in the study
Patients in any stage of the CML are included
Patients with concurrent malignancies other than CML
2. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive therapy. Hence, patients with any of the following diseases other than CML who are considered not suitable by the physician will not be recruited for this research project:
Cardiovascular Disease Fluid Retention, Bone Marrow suppression
Gastrointestinal Disorders Hepatic Impairment Hypothyroidism
Renal Impairmen
Patients treated with any other chemotherapeutic drugs in addition to imatinib
Female patients who are pregnant
Patients who have not completed 18 years of age
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of SNPs Genetic Biomarkers that are <br/ ><br>associated with the Imatinib clinical response Toxicity and Resistance <br/ ><br>Timepoint: 3rd month 6th month 1 year <br/ ><br>
- Secondary Outcome Measures
Name Time Method Identification of SNPs Genetic Biomarkers that are <br/ ><br>associated with the Imatinib ResistanceTimepoint: <br/ ><br>Third Month 6th month one year